NO20091489L - Tiazolpyrazolopyridiner som CRF1 reseptorantagonister - Google Patents

Tiazolpyrazolopyridiner som CRF1 reseptorantagonister

Info

Publication number
NO20091489L
NO20091489L NO20091489A NO20091489A NO20091489L NO 20091489 L NO20091489 L NO 20091489L NO 20091489 A NO20091489 A NO 20091489A NO 20091489 A NO20091489 A NO 20091489A NO 20091489 L NO20091489 L NO 20091489L
Authority
NO
Norway
Prior art keywords
receptor antagonists
pyrazolopyridines
thiazole
crf1 receptor
crf1
Prior art date
Application number
NO20091489A
Other languages
English (en)
Inventor
Erik James Hembre
Jason Kenneth Myers
Chafiq Hamdouchi Hamdouchi
Takako Takakuwa
Zhaogen Chen
Philip Arthur Hipskind
James Lee Toth
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38924802&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091489(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20091489L publication Critical patent/NO20091489L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Foreliggende oppfinnelse angår forbindelser med formel I: farmasøytiske sammensetninger derav, og anvendelse derav som corticotropin frigivende faktor 1 (CRF1) reseptorantagonister ved behandling av psykiatriske og neuroendokrine forstyrrelser, neurologiske sykdommer og metabolittisk syndrom.
NO20091489A 2006-09-20 2009-04-16 Tiazolpyrazolopyridiner som CRF1 reseptorantagonister NO20091489L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82626406P 2006-09-20 2006-09-20
PCT/US2007/078605 WO2008036579A1 (en) 2006-09-20 2007-09-17 Thiazole pyrazolopyrimidines as crf1 receptor antagonists

Publications (1)

Publication Number Publication Date
NO20091489L true NO20091489L (no) 2009-04-16

Family

ID=38924802

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091489A NO20091489L (no) 2006-09-20 2009-04-16 Tiazolpyrazolopyridiner som CRF1 reseptorantagonister

Country Status (34)

Country Link
US (1) US8030304B2 (no)
EP (1) EP2094709B1 (no)
JP (1) JP5161226B2 (no)
KR (1) KR101088239B1 (no)
CN (1) CN101516887B (no)
AR (1) AR062886A1 (no)
AT (1) ATE481405T1 (no)
AU (1) AU2007297421B2 (no)
BR (1) BRPI0717023B8 (no)
CA (1) CA2663511C (no)
CL (1) CL2007002693A1 (no)
CR (1) CR10682A (no)
CY (1) CY1110854T1 (no)
DE (1) DE602007009305D1 (no)
DK (1) DK2094709T3 (no)
EA (1) EA015179B1 (no)
ES (1) ES2350282T3 (no)
HK (1) HK1132505A1 (no)
HR (1) HRP20100516T1 (no)
IL (1) IL197614A (no)
MA (1) MA30798B1 (no)
MX (1) MX2009003125A (no)
MY (1) MY146388A (no)
NO (1) NO20091489L (no)
NZ (1) NZ575572A (no)
PE (1) PE20081377A1 (no)
PL (1) PL2094709T3 (no)
PT (1) PT2094709E (no)
RS (1) RS51545B (no)
SI (1) SI2094709T1 (no)
TN (1) TN2009000095A1 (no)
TW (1) TWI402269B (no)
UA (1) UA96458C2 (no)
WO (1) WO2008036579A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP5524221B2 (ja) 2008-10-02 2014-06-18 イーライ リリー アンド カンパニー 合成中間体としてのチアゾリル−ピラゾロピリミジン化合物および関連合成方法
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP3096756A1 (en) 2014-01-21 2016-11-30 Neurocrine Biosciences, Inc. Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
PL236355B1 (pl) * 2015-04-02 2021-01-11 Celon Pharma Spolka Akcyjna Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
EP3510029A4 (en) 2016-09-07 2020-03-11 The Regents of The University of California ALLOSTERIC CORTICOTROPIN RELEASING FACTOR-1 (CRFR1) ANTAGONISTS TO REDUCE P-TAU AND IMPROVE THE COGNITION
BR112020002967A2 (pt) 2017-08-14 2020-08-11 Spruce Biosciences, Inc. antagonistas de receptor de fator de liberação de corticotropina
MX2019015318A (es) * 2017-08-14 2020-07-20 Spruce Biosciences Inc Antagonistas del receptor del factor liberador de corticotropina.
EP3784233A4 (en) * 2018-04-27 2022-03-02 Spruce Biosciences, Inc. METHODS OF TREATMENT OF TESTIC AND OVARIAN ADRENAL TUMORS
CN109134481B (zh) * 2018-08-07 2021-05-14 中山大学 一种取代吡咯色原酮类化合物或其药学上可接受的盐及其制备方法和应用
TWI714231B (zh) * 2018-09-04 2020-12-21 美商美國禮來大藥廠 2,6-二胺基吡啶化合物
EP4069697A1 (en) * 2019-12-04 2022-10-12 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
GR1010096B (el) * 2020-07-02 2021-10-08 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, Πυραζολο[1,5-a]πυριμιδινες με δραση αναστολης της αυτοταξινης
MX2023001688A (es) * 2020-08-12 2023-02-22 Spruce Biosciences Inc Metodos y composiciones para tratar el sindrome de ovario poliquistico.
US20240024330A1 (en) 2020-08-26 2024-01-25 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof
WO2023091684A1 (en) * 2021-11-19 2023-05-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof
WO2023163945A1 (en) * 2022-02-23 2023-08-31 Crinetics Pharmaceuticals, Inc. Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ258690A (en) 1992-12-17 1997-01-29 Pfizer Pyrrolopyrimidines and pharmaceutical compositions containing such compounds; intermediate pyrrole compounds
DK0880523T3 (da) * 1996-02-07 2007-03-26 Neurocrine Biosciences Inc Pyrazolopyrimidiner som CRF-receptorantagonister
SK286461B6 (sk) * 1996-07-24 2008-10-07 Bristol-Myers Squibb Pharma Company [1,5-a]-Pyrazolo-1,3,5-triazíny, ich použitie a farmaceutické kompozície na ich báze
EP0915880B1 (en) 1996-07-24 2007-10-10 Bristol-Myers Squibb Pharma Company Azolo triazines and pyrimidines
ATE340176T1 (de) 1996-08-28 2006-10-15 Pfizer Substituierte 6,5-heterobicyclische-derivate
EP1040831A3 (en) * 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
WO2000059908A2 (en) 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
CZ20021089A3 (cs) 1999-09-30 2002-11-13 Neurogen Corporation Aminosustituované pyrazolo[1,5-a]-1,5-pyrimidiny a pyrazolo[1,5-a]-1,3,5-triaziny
RS50863B (sr) * 2001-03-13 2010-08-31 Bristol-Myers Squibb Pharma Company 4-(2-butilamino)-2,7-dimetil-8-(2-metil-6-metoksipirid-3-il) pirazolo/1,5a/-1,3,5-triazin,njegovi enantiomeri i farmaceutski prihvatljive soli kao ligandi receptora za faktor koji oslobađa kortikotropin
MY143499A (en) * 2003-12-22 2011-05-31 Sb Pharmco Inc Crf receptor antagonist and methods relating thereto

Also Published As

Publication number Publication date
PT2094709E (pt) 2010-10-04
DE602007009305D1 (de) 2010-10-28
HRP20100516T1 (hr) 2010-10-31
AU2007297421A1 (en) 2008-03-27
PL2094709T3 (pl) 2011-02-28
EP2094709A1 (en) 2009-09-02
EP2094709B1 (en) 2010-09-15
ES2350282T3 (es) 2011-01-20
CY1110854T1 (el) 2015-06-10
BRPI0717023A2 (pt) 2014-03-11
AR062886A1 (es) 2008-12-10
EA015179B1 (ru) 2011-06-30
US20100222339A1 (en) 2010-09-02
ATE481405T1 (de) 2010-10-15
TW200821312A (en) 2008-05-16
BRPI0717023B8 (pt) 2021-05-25
AU2007297421B2 (en) 2012-03-08
CR10682A (es) 2009-08-13
MY146388A (en) 2012-08-15
UA96458C2 (ru) 2011-11-10
CA2663511A1 (en) 2008-03-27
TN2009000095A1 (en) 2010-08-19
KR20090052366A (ko) 2009-05-25
EA200970303A1 (ru) 2009-10-30
CN101516887A (zh) 2009-08-26
WO2008036579A1 (en) 2008-03-27
IL197614A (en) 2012-10-31
CL2007002693A1 (es) 2008-04-18
PE20081377A1 (es) 2008-09-18
JP2010504344A (ja) 2010-02-12
HK1132505A1 (en) 2010-02-26
US8030304B2 (en) 2011-10-04
SI2094709T1 (sl) 2011-01-31
NZ575572A (en) 2011-10-28
CA2663511C (en) 2012-12-04
JP5161226B2 (ja) 2013-03-13
BRPI0717023B1 (pt) 2019-11-19
CN101516887B (zh) 2011-11-02
MA30798B1 (fr) 2009-10-01
TWI402269B (zh) 2013-07-21
DK2094709T3 (da) 2010-12-06
RS51545B (en) 2011-06-30
MX2009003125A (es) 2009-05-28
IL197614A0 (en) 2009-12-24
KR101088239B1 (ko) 2011-11-30

Similar Documents

Publication Publication Date Title
NO20091489L (no) Tiazolpyrazolopyridiner som CRF1 reseptorantagonister
EA200970302A1 (ru) Тиофенпиразолопиримидиновые соединения
ATE424402T1 (de) Imidazopyridinverbindungen
GB0625648D0 (en) Compounds
MA32175B1 (fr) Oxadiazoanthracènes pour le traitement du diabète
NO20070489L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
MY148544A (en) Pyridyl piperidine orexin receptor antagonists
MX2007007103A (es) Derivados espiro como inhibidores de lipoxigenasa.
NO20083567L (no) Hydantoinderivater for behandling av inflammatoriske forstyrrelser
WO2010018109A3 (en) Substituted aminotetralines
UA99524C2 (ru) Триазолопроизводные, полезные для лечения болезней
NO20084363L (no) 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister
DE602007010781D1 (de) N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid-derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
WO2010142766A3 (en) Pyrimidine derivatives as zap-70 inhibitors
ATE538100T1 (de) Aminotetrahydroindazoloessigsäuren
MX2008002805A (es) Derivados de carboxamida como antagonistas del receptor muscarinico.
WO2010018112A3 (en) Monoaryl aminotetralines
ATE467636T1 (de) Pyrazoloä3 , 4-düazepinderivate als histamin-h3- antagonisten
WO2008074803A8 (en) 4-benzyl-l ( 2h) -phthalazinones as h1 receptor antagonists
WO2006078554A3 (en) Cgrp receptor antagonists
GB0514811D0 (en) Compounds
ATE455111T1 (de) Einen azepin-kern enthaltende antagonisten des histaminrezeptors
GB0407025D0 (en) Novel compounds
NO20064806L (no) Formamidderivater anvendelige som adenoceptor

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application